← Back to Search

Anti-metabolites

Capecitabine for Advanced Breast Cancer

Phase 2
Waitlist Available
Research Sponsored by Pharmatech Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 and over, female
Renal criteria: Creatinine no greater than 1.5 times ULN, Creatinine clearance at least 50 mL/min
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is comparing the effectiveness of two different doses of capecitabine in treating women who have advanced or metastatic breast cancer.

Who is the study for?
This trial is for women over 18 with advanced or metastatic breast cancer. They must have a certain level of blood cells, liver and kidney function, and no severe heart conditions. Participants need measurable tumor lesions and should not be pregnant, nursing, or have had recent heart attacks. No history of bad reactions to similar drugs or uncontrolled infections.Check my eligibility
What is being tested?
The study is testing two different doses of capecitabine, a chemotherapy drug, to see which one works better in stopping the growth or spread of breast cancer cells in women with advanced stages of the disease.See study design
What are the potential side effects?
Capecitabine can cause side effects like diarrhea, hand-foot syndrome (redness/pain/swelling), nausea/vomiting, fatigue, mouth sores; some may be more common at higher doses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 18 or older.
Select...
My kidney function tests are within the required range.
Select...
I am mostly able to care for myself and carry out daily activities.
Select...
My breast cancer is confirmed and has spread beyond the breast.
Select...
My heart is healthy with no significant diseases or recent heart attacks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Pharmatech OncologyLead Sponsor
4 Previous Clinical Trials
180 Total Patients Enrolled
1 Trials studying Breast Cancer
Sandy MarcusStudy ChairPharmatech Oncology
1 Previous Clinical Trials
1 Trials studying Breast Cancer

Media Library

Capecitabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00026442 — Phase 2
Breast Cancer Research Study Groups:
Breast Cancer Clinical Trial 2023: Capecitabine Highlights & Side Effects. Trial Name: NCT00026442 — Phase 2
Capecitabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00026442 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many locations are currently running this experiment?

"The trial is operational in 13 different medical sites, with the major facilities located at Charleston Hematology-Oncology (South carolina), Oncology Clinic (Colorado Springs), and Maryland Hematology/Oncology Associates (Baltimore)."

Answered by AI

Are there any vacancies to partake in this clinical investigation?

"Unfortunately, the trial is no longer recruiting as per information on clinicaltrials.gov; this study was initially published in November 2001 and last updated December 2013. However, there are 2,600 other trials searching for patients at present."

Answered by AI

Does this treatment pose any safety risks for those who use it?

"This treatment is estimated to be moderately safe, as indicated by its rating of 2. This assessment was determined based on the Phase 2 trial which provided data regarding safety but lacked proof of efficacy."

Answered by AI
~15 spots leftby Mar 2025